EPCLUSA Reviews (SOFOSBUVIR AND VELPATASVIR)

Average Rating: 5.0 (2 Ratings)

Filter Results

Compare EPCLUSA with similar:

 Type: Rx Drug

  

EPCLUSA  (SOFOSBUVIR AND VELPATASVIR):  This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.   FDA Approval Date: 2016-06-28 (Sources: U.S. Centers for Medicare Services, FDA)

  

Results are sorted by Date added.

Key to Ratings: 1=LOW (I would not recommend taking this medicine.)
5=HIGH (this medicine cured me or helped me a great deal.)

Page: 1


RATING  REASONSIDE EFFECTS FOR EPCLUSACOMMENTSSEXAGEDURATION/
DOSAGE		DATE ADDED
 
 5  Hep C Insomnia the first week only. Dry mouth. Low energy. Treatment was easy with very minor side effects. Virus was cleared at 8 weeks, finished all 12 weeks. Virus still clear . F 66 3 months
30mg 1X day		 10/13/2020
 5  Hepatitis c A little bit of body aches if I didn't drink enough water. Super easy treatment! F 50 87 days
 7/10/2020
  

EPCLUSA  (SOFOSBUVIR AND VELPATASVIR):  This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.   FDA Approval Date: 2016-06-28 (Sources: U.S. Centers for Medicare Services, FDA)

     

BACK TO TOP